Certara (HAM:700) Institutional Ownership : 56.13% (As of Jun. 20, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Certara Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Certara's institutional ownership is 56.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Certara's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Certara's Float Percentage Of Total Shares Outstanding is 75.19%.

Certara Institutional Ownership Historical Data

The historical data trend for Certara's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara Institutional Ownership Chart

Certara Historical Data

The historical data trend for Certara can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	58.56	58.17	56.72	56.50	55.70	55.21	55.21	57.40	56.43	56.13

Certara Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Certara (HAM:700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (HAM:700) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CERT:USA

Address

100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540

Website

https://www.certara.com

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.

Certara (HAM:700) Headlines

No Headlines